🇺🇸

US SEC Filing Intelligence

· daily

Significant Contract Modifications ($10M+) — May 07, 2026

These 18 significant contract modifications totaling $1,337,470,948 in obligations are overwhelmingly civilian (17/18 contracts, ~99.9% value), with only ABSS Solutions' $113M GSA award at Lackland AFB qualifying as defense-related. Dominant themes include IT/services for HHS/CMS (VENTERA $84M, Flexion $49M), DHS/ICE (Palantir $86M, GEO Group $51M), and DOE (BWXT $80M HALEU processing), alongside engineering/health R&D across VA, NOAA, and NASA. Highest-conviction bullish signal is BWXT Nuclear Operations Group's $79.8M DOE NNSA non-competed HALEU processing award (strength 7/10, materiality 8/10), signaling durable nuclear revenue through 2028. Key risk is pervasive high fixed-price execution risk across 12+ contracts (e.g., VES $106M VA fully committed but past-dated), compounded by $0 outlays on future-dated awards like Palantir and Olsson ($68.7M Interior). Watch multi-year option exercises, especially VENTERA's $18M upside to $102M CMS ceiling.

18 total filings
· daily

Federal IT & Cybersecurity Contracts — May 07, 2026

This digest covers $390,576,263 in total obligations across 6 Federal IT & Cybersecurity contracts, all civilian agency awards with 0 defense-related, spanning HHS/CMS, HUD, State, DOE, and VA. Dominant theme is steady civilian IT infrastructure and application support spending, led by HHS/CMS at ~$133M combined for VENTERA LLC ($83.7M) and Flexion Inc ($49.1M). Highest-conviction bullish signal is VENTERA LLC's $83.7M CMS QualityNet order with $58.8M already outlayed, signaling strong execution in healthcare IT. Key risk is high pricing risk on firm-fixed price structures across multiple awards like Microtechnologies LLC's $76.5M HUD contract; watch outlay progress and option exercises amid medium-term performance periods to 2027.

6 total filings
· daily

All DOE Contracts — May 07, 2026

Two DOE civilian contracts totaling $135,168,251 in obligations highlight bullish signals in nuclear processing and IT services, with zero defense-related awards. BWX Technologies, Inc.'s subsidiary BWXT Nuclear Operations Group, Inc. leads with the highest-conviction bullish signal via a $79,811,931 non-competed firm fixed price delivery order from DOE NNSA for HALEU processing through 2028, representing specialized nuclear revenue. Accenture Federal Services LLC adds $55,356,320 in Time and Materials IT support from DOE Headquarters Procurement Services through 2027. Dominant themes center on DOE's NNSA nuclear priorities and headquarters IT modernization. Key risk: monitor progress on BWXT's remaining $23.8M obligation beyond $55.9M outlayed and option exercises to $116.7M ceiling, given high pricing risk.

2 total filings
· daily

General Federal Contracts — May 07, 2026

Across 18 contracts totaling $1,337,470,948 in obligations, only 1 (ABSS Solutions Inc.'s $113M GSA award at Lackland AFB) is defense-related, with the remaining 17 skewed toward civilian agencies including GSA, VA, DHS, DOE, and HHS emphasizing IT services, health R&D, and facilities support. Dominant themes include civilian IT modernization and healthcare data management, with bullish signals for Palantir Technologies ($86M DHS ICE SaaS), BWXT Nuclear Operations ($79M DOE HALEU processing), and Lynker Corporation ($98M NOAA environmental support) highlighting multi-year revenue visibility. Highest-conviction bullish signal is BWXT's non-competed $79.8M DOE award (7/10 strength, 8/10 materiality) for specialized nuclear work through 2028, aligning with DOE NNSA priorities. Key risk is pervasive high fixed-price execution risk across 12 contracts (e.g., VES $106M VA, GEO Group $51M DHS), amplified by $0 outlays on future-dated awards like Palantir and Olsson Industrial Electric ($68M DOI). Watch multi-year option exercises, particularly for Booz Allen Hamilton's $112M Army SETA (potential to $144M) and Venterra LLC's $83M CMS IT ($101M ceiling).

18 total filings
· daily

All NASA Contracts — May 07, 2026

NASA's two contracts totaling $111,990,661 in obligations, awarded to nonprofit entities THE CHARLES STARK DRAPER LABORATORY, INC. ($56,933,211) and UTAH STATE UNIVERSITY SPACE DYNAMICS LABORATORY ($55,057,450), represent 100% civilian space R&D spending with 0/2 defense-related awards during the May 07, 2026 period. The dominant agency theme is NASA's sustained investment in lunar payloads via CLPS (Draper Lab) and atmospheric research via AWE (Utah State), both under full and open competition with significant outlays already at $43.3M and $48.2M respectively. Overall signals remain neutral (avg 3.5/10 strength), reflecting steady nonprofit funding but limited equity upside. Highest-conviction signal is outlay momentum toward full obligations amid long-duration performance periods through 2026-2027. Key risk: high pricing risk on Draper's firm fixed price structure; watch option exercises to reach $84.3M and $57.3M ceilings.

2 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 07, 2026

Across 50 SEC filings dated May 7, 2026, primarily Q1 FY2026 results for diverse firms (despite Consumer Staples labeling, spanning consumer brands, biotech, energy, finance), revenue trends are mixed with standout growth in branded consumer plays (Celsius +138% YoY to $782.6M, Kontoor Brands +45% to $613M continuing ops, Tapestry +21% to $1.92B) contrasting declines (Aspen Aerogels -52% to $37.9M, Krispy Kreme -2.2% to $367M, Rockwell Medical -8% to $17.3M). Margin expansions prevalent in 7/15 detailed reporters (ARKO fuel +20.1% to 48c/gal, Krispy Kreme EBITDA +380bps to 9%, Callaway gross +250-260bps), but compressions hit growth firms (Claritev EBITDA margin -140bps to 60%, Celsius gross -400bps to 48.3%). Guidance largely raised or steady (Kontoor FY rev $3.41-3.46B up, Callaway sales $2.015-2.07B raised $35-70M, Tapestry ~$7.95B +14%; ARKO unchanged $245-265M EBITDA), signaling management conviction amid YoY improvements in net losses (ARKO -56% narrower, Climb Bio -34%). Capital allocation aggressive with buybacks (Kontoor $750M new auth, GigaCloud $12.3M Q1/$68M remain, Callaway 5.6M shares), dividends (ARKO $0.03/sh, Dorian LPG irregular $1.00/sh), and debt reduction (ARKO $206M via IPO). Biotech pipeline catalysts dense (Climb Bio Fast Track/FDA orphan, Monte Rosa Phase 2 H2 2026), while cash flows deteriorated in 6/12 (GigaCloud op cash $(21.7)M vs +$9.4M YoY, Claritev FCF $(92.5)M worse). Portfolio-level: 14/22 Q1 reporters avg +28% rev growth but -15% avg op cash YoY; mixed sentiment (18/22 mixed) implies selective opportunities in margin outperformers and guidance raisers.

22 high priority 28 medium 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 07, 2026

Across the 50 SEC filings from Dow Jones 30-related streams, dominant themes include robust M&A and SPAC activity in nuclear/energy (Hennessy/ONE Nuclear, General Fusion, Catalyst Pharma acquisition), explosive revenue growth in consumer products (Celsius +138% YoY, Kontoor +45% YoY), and biotech pipeline advancements amid cash burns (Vera PDUFA July 2026, Evommune Phase 2b readouts). Period-over-period trends show 18/25 detailed filers with YoY revenue growth averaging +35% (range -4% to +167%), but margins mixed with 9 expansions (avg +200 bps, e.g., MasterCraft +420 bps) vs 7 compressions (avg -150 bps, e.g., Celsius -400 bps); EBITDA improvements in 14 cases (avg +50%). Critical developments: 5 M&A/mergers (e.g., Catalyst $4.1B at 21-28% premium, MasterCraft vote May 12), 4 guidance raises (Kontoor revenue to $3.41-3.46B, AvePoint ARR $523-529M), and equity/debt raises ($405M Avalo, $750M Booking notes). Portfolio-level patterns flag sector rotation opportunities in consumer/energy (+100%+ growth outliers) vs telecom/utilities caution (Optimum -4% rev, impairments), with capital returns via buybacks ($750M Kontoor, $24M Celsius) signaling conviction amid mixed sentiment (14/25 mixed, 6 positive). Implications: Bullish for acquisitive consumer/biotech names, monitor nuclear catalysts for DJ30 energy proxies.

29 high priority 21 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 07, 2026

Across 15 DEF 14A filings dated May 7, 2026, proxy season reveals a cluster of 12 annual/special meetings scheduled June 16-23, 2026, primarily for routine director elections (14/15 filings), say-on-pay advisory votes (9/15), auditor ratifications (9/15), and equity incentive plan approvals/amendments (4/15), signaling standard governance focus with no widespread financial declines disclosed. High insider ownership stands out in Capstone Holding (39.29% by directors/officers, CEO 21.12%/26.77% voting), indicating strong alignment, while positive transformation narratives in Designer Brands (inventory productivity, profitability gains despite tariffs) and Okta (AI agent era shift, board refresh) contrast neutral/mixed sentiment elsewhere. No explicit YoY/QoQ revenue or margin declines noted across filings, but governance risks emerge in Wave Life Sciences' redomiciliation (75% approval threshold, shareholder rights changes) and equity dilutions in CXApp/SurgePays (20%+ share issuances). Fund-heavy filings (6/15) show trustee elections post-acquisitions with continuity assurances. Portfolio implication: monitor June vote outcomes for governance catalysts, favoring high-ownership names like Capstone for conviction plays amid low-materiality routines.

15 high priority 15 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 07, 2026

The IPO Pipeline stream features two neutral-sentiment filings on May 7, 2026: Terra Property Trust's S-4 outlining REIT operations, debt management, and liquidity exploration via direct listing or non-traded REIT conversion, and Eloxx Pharmaceuticals' initial S-1 IPO registration with minimal disclosures. Terra demonstrates proactive debt reduction, including full repayment of $36.8M Terra LLC Notes, Goldman Sachs repurchase agreement in June 2025, and revolving credit line on July 1, 2025, maintaining a stable 1.23x debt-to-equity ratio as of Dec 31, 2025, amid $130.6M total indebtedness as of March 31, 2026. No explicit YoY/QoQ financial trends or revenue metrics are available across filings, but Terra's portfolio diversification across 9 markets and 7 states signals resilience in commercial real estate credit. Eloxx provides no financials, sector details, or use-of-proceeds, highlighting early-stage opacity typical of S-1s. Overarching theme: Early liquidity catalysts in REIT and pharma spaces amid stable leverage for Terra; investors should monitor SEC reviews for pricing and terms, positioning for potential outperformance in underrepresented IPO sectors.

2 high priority 2 total filings
· daily

US Merger & Acquisition SEC Filings — May 07, 2026

A surge in SPAC IPO activity dominates the 19 filings, with 7 blank-check companies (Irenic, ARC Group, Mountain Crest, RRE Ventures, Forefront Tech, GP-Act III) completing IPOs raising aggregate ~$883M at $10/unit, signaling robust appetite for de-SPAC opportunities amid extended deadlines to Nov/July 2026. Energy sector consolidation peaks with Devon Energy completing undisclosed asset acq/disposition and Coterra merger (0.70 Devon shares/share), leading to delisting and cessation of reporting, while VSE Corp's $2.025B PAG aviation acq boosts pro forma 2025 revenue ~50% and targets >20% EBITDA margins. Media (Gray $171M stations) and construction (Suncrete Nelson Bros acq) show accretive bolt-ons expanding footprints, contrasted by Carnival's high-risk restructuring (delisting, control change) and neutral filings lacking details (Sculptor, Shuttle). No broad YoY/QoQ declines noted, but increased debt (VSE $900M Term Loan B, Acura $10.3M principal) and dilutions (Blue Acq 12% incentive pool) emerge; positive sentiments in 9/19 filings drive M&A momentum. Portfolio trend: Acquisitions accretive across sectors (avg implied revenue lift 30-50%), SPAC trust funding intact for catalysts.

19 high priority 19 total filings
· daily

Biotech Small-Cap Approvals — May 06, 2026

The May 6, 2026 period delivered 6 Other approvals in the biotech small-cap stream (0 NME, 0 biosimilar, 0 label expansion), generating 3 bullish and 3 neutral signals with no bearish outcomes. While no dominant therapeutic area theme is evident, oncology stands out with three approvals including label expansions for TRABECTEDIN (APOTEX INC) and RUXOLITINIB PHOSPHATE (INCYTE CORPORATION) alongside the highest-conviction VEPDEGESTRANT NME for ARVINAS OPERATIONS INC, signaling first-in-class potential with 5-year NCE exclusivity and strong unmet need. Biosimilar approvals for SITAGLIPTIN (BIOCON PHARMA LTD), TORSEMIDE (MICRO LABS), and MIRABEGRON (DEVA HOLDING AS) introduce neutral entrant upside but bearish competitive erosion risks for originators like Merck (Januvia) and Astellas (Myrbetriq). Key risk/watch item: post-approval launch execution for ARVINAS OPERATIONS INC's VEPDEGESTRANT amid competitive oncology dynamics.

6 total filings
· daily

Orphan Drug Approvals — May 06, 2026

During May 6-6, 2026, the FDA issued 1 orphan drug approval, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 1 Other, generating 1 bullish signal. INCYTE CORPORATION's label expansion for RUXOLITINIB PHOSPHATE (JAKAFI XR) marks the period's sole event, signaling incremental upside in the orphan space without a dominant therapeutic area theme due to the single approval. This represents the highest-conviction signal, offering INCYTE CORPORATION potential revenue diversification from an established asset amid NOT_DISCLOSED commercial details. No bearish or neutral signals emerged. Key risk/watch item: limited visibility into peak sales, exclusivity, pricing, and market position requires monitoring post-approval performance.

1 total filings
· daily

New Drug Approvals (Original) — May 06, 2026

This week's 6 FDA 'Other' approvals (0 NME, 0 biosimilar, 0 label expansion) feature a mix of label expansions, biosimilars, and one NME, with 3 bullish and 3 neutral signals but no dominant therapeutic area clustering. Highest-conviction signal is ARVINAS OPERATIONS INC's NME approval for VEPDEGESTRANT (VEPPANU), a strong pipeline execution indicator with 8/10 strength and materiality, implying 5-year NCE exclusivity and significant commercial upside. Bullish label expansions for TRABECTEDIN (APOTEX INC) and RUXOLITINIB PHOSPHATE (JAKAFI XR, INCYTE CORPORATION) enhance sponsor franchises, while neutral biosimilar approvals for SITAGLIPTIN (BIOCON PHARMA LTD), TORSEMIDE (MICRO LABS), and MIRABEGRON (DEVA HOLDING AS) pose modest competitive entry without originator erosion quantified. Key risk/watch item: competitive dynamics from biosimilar entrants potentially pressuring originators over 2-3 years.

6 total filings
· daily

VA Healthcare & Services Contracts — May 06, 2026

These two VA Healthcare & Services contracts aggregate $328,828,352 in total obligations, with a 0/2 defense-related split, entirely within civilian VA exposure. The dominant agency theme is Department of Veterans Affairs support services, led by Vendor Resource Management, Inc.'s $200,641,730 real estate management award (materiality 6/10) and Favor TechConsulting, LLC's $128,186,621 IT development delivery order (materiality 5/10). Highest-conviction signal is neutral (avg 4/10 strength) across both full-and-open competition awards to private firms. A key risk is low outlay progress—$38,359,535 (19%) for Vendor Resource and $16,478,924 (13%) for Favor TechConsulting—signaling potential execution delays. Watch option exercises toward $374M and $185M ceilings ahead of 2025-09-30 and 2026-09-29 ends.

2 total filings
· daily

New Federal Contractors — May 06, 2026

These four new federal civilian contracts total $737,191,282 in obligations, with zero defense-related awards across NASA, VA (two contracts), and GSA. Dominant themes include long-term civilian infrastructure modernization (GSA construction) and VA real estate/IT services, reflecting steady non-DOD spending priorities. Highest-conviction signal is bullish on Hensel Phelps Construction Co.'s $188,297,215 GSA contract, with 76% ($143M) outlayed and performance through mid-2026. Neutral signals dominate for Peraton Inc. ($220M NASA), Vendor Resource Management Inc. ($200M VA), and Favor Techconsulting LLC ($128M VA), due to partial execution. Key risk is low outlay progress on VA contracts (e.g., $38M of $200M for Vendor Resource Management), vulnerable to budget scrutiny amid CR uncertainty.

4 total filings
· daily

Significant Contract Modifications ($10M+) — May 06, 2026

These four significant contract modifications total $737,191,282 in obligations, all civilian with zero defense-related awards across NASA, VA (two contracts), and GSA. Dominant themes include VA real estate management and IT services alongside NASA R&D operations and GSA construction, reflecting steady civilian infrastructure and support spending. Highest-conviction signal is bullish for Hensel Phelps Construction Co.'s $188,297,215 GSA contract, with 76% ($143M) outlayed and performance to 2026. Neutral signals dominate for Peraton Inc. ($220M NASA), Vendor Resource Management Inc. ($200M VA), and Favor Techconsulting LLC ($128M VA) due to partial execution. Key risk is low outlay progress in VA contracts (e.g., only 19% for Vendor Resource, 13% for Favor), signaling potential execution hurdles amid fixed-price structures.

4 total filings
· daily

Contract Deobligations Alert — May 06, 2026

These four civilian contract deobligations total $737,191,282 in obligations with 0/4 defense-related, highlighting steady execution in NASA, VA, and GSA programs but no DOD exposure. Dominant themes include VA real estate/IT services ($328.8M across two awards) and infrastructure construction via GSA. Highest-conviction bullish signal is Hensel Phelps Construction Co.'s $188M GSA contract with 76% ($143M) outlayed and low pricing risk through 2026. Key watch item: low outlay progress in VA contracts (e.g., Vendor Resource Management's $38M of $200M and Favor TechConsulting's $16M of $128M), signaling potential non-exercise of options or execution delays.

4 total filings
· daily

Contract Option Exercises — May 06, 2026

Four civilian agency contract option exercises totaling $737,191,282 in obligations highlight steady federal spending on long-term services and infrastructure, with 0/4 defense-related awards spanning NASA, VA (two contracts), and GSA. VA dominates with $328,828,351 combined across Vendor Resource Management ($200M) and Favor TechConsulting ($128M) for real estate and IT services. Highest-conviction bullish signal is Hensel Phelps Construction Co.'s $188,297,215 GSA construction project at 76% outlay ($143M disbursed), signaling reliable revenue through 2026. Peraton Inc.'s $220M NASA balloon facility operations adds neutral long-term NASA exposure at 41% outlay. Key risk: Low outlay execution in VA contracts (Vendor Resource at 19%/$38M, Favor TechConsulting at 13%/$16M), vulnerable to budget scrutiny or non-exercise of options.

4 total filings
· daily

Federal Professional Services Contracts — May 06, 2026

This digest covers a single $220,065,714 obligation contract to Peraton Inc. from NASA Goddard Space Flight Center, comprising 100% civilian awards with 0/1 defense-related. The dominant theme is steady NASA funding for GOCO R&D facility operations (PSC M1HA) via a 10-year cost-plus-fixed-fee structure under full and open competition. Highest-conviction signal is neutral (5/10 strength, 6/10 materiality), reflecting $89.9M outlayed (41% of obligation) and $21.5M estimated annual revenue through 2025. Partial execution includes $71.6M in 261 subawards, indicating subcontractor reliance. Key risk: contract expiration on 2025-04-30 with $130M remaining obligation, requiring monitoring for follow-on awards.

1 total filings